000			02160nam a2200493 i 4500
999			_c272757 _d272757
001			on1042074892
003			OCoLC
005			20180801080941.0
006			m o d f
007			cr bn||||a||||
008			180627s2018 dcu ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1008-I (online)
086	0		_aY 1.1/8:115-726
099			_aY 1.1/8:115-726
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Energy and Commerce,
245	1	0	_aMedicaid Pharmaceutical Home Act of 2018 : _breport together with additional views (to accompany H.R. 5808) (including cost estimate of the Congressional Budget Office).
264		1	_a[Washington, D.C.] : _b[U.S. Government Publishing Office], _c[2018]
300			_a1 online resource (36 pages).
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aReport / 115th Congress, 2d session, House of Representatives ; _v115-726
500			_a"June 12, 2018."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource, PDF version; title from caption (Govinfo, viewed June 27, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Energy and Commerce. _tMedicaid Pharmaceutical Home Act of 2018 _w(OCoLC)1042086032
810	1		_aUnited States. _bCongress. _bHouse. _tReport ; _v115-726.
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo94185
050	1	4	_aKF32 _b.E55 2018v
610	1	0	_aUnited States. _tSocial Security Act.
610	1	0	_aUnited States. _bFood and Drug Administration _xRules and practice.
650		0	_aMedicaid _zUnited States.
650		0	_aMedicare _zUnited States.
650		0	_aDrugs _xPrescribing _zUnited States _xManagement.
650		0	_aOpioid abuse _xTreatment _zUnited States _xCosts.
650		0	_aDrug development _xGovernment policy _zUnited States.
650		0	_aDrugs _xGeneric substitution _xGovernment policy _zUnited States.
655		7	_aLegislative materials. _2lcgft
942			_2sudocs _c8